Edition:
United Kingdom

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

39.55USD
14 Dec 2018
Change (% chg)

$0.18 (+0.46%)
Prev Close
$39.37
Open
$38.58
Day's High
$40.24
Day's Low
$38.58
Volume
219,635
Avg. Vol
193,366
52-wk High
$68.15
52-wk Low
$37.29

Chart for

About

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.... (more)

Overall

Beta: --
Market Cap(Mil.): $4,359.11
Shares Outstanding(Mil.): 78.97
Dividend: --
Yield (%): --

Financials

  FGEN.OQ Industry Sector
P/E (TTM): -- 69.71 34.39
EPS (TTM): -1.92 -- --
ROI: -28.39 9.01 14.96
ROE: -58.84 10.15 16.52

Boost for 'made in China' medicine as Chi-Med wins key approval

LONDON Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

05 Sep 2018

UPDATE 1-Boost for "made in China" medicine as Chi-Med wins key approval

* Green light shows growing strength of Chinese biotech (Updates with CEO interview, latest shares, background)

05 Sep 2018

Boost for "made in China" medicine as Chi-Med wins key approval

LONDON, Sept 5 Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

05 Sep 2018

Earnings vs. Estimates